The epidermal growth factor receptor (EGFR), through the MAP kinase and PI3K‐Akt-mTOR axis, plays a pivotal role in colorectal cancer (CRC) pathogenesis. The membrane‐associated NEU3 sialidase interacts with and desialylates EGFR by promoting its dimerization and downstream effectors’ activation. Among the targeted therapies against EGFR, the monoclonal antibody cetuximab is active only in a subgroup of patients not carrying mutations in the MAP kinase pathway. In order to better understand the EGFR‐NEU3 interplay and the mechanisms of pharmacological resistance, we investigated the role of NEU3 deregulation in cetuximab‐treated CRC cell lines transiently transfected with NEU3 using Western blot analysis. Our results indicate that NEU3 overexpression can enhance EGFR activation only if EGFR is overexpressed, indicating the existence of a threshold for NEU3‐mediated EGFR activation. This enhancement mainly leads to the constitutive activation of the MAP kinase pathway. Consequently, we suggest that the evaluation of NEU3 expression cannot entirely substitute the evaluation of EGFR because EGFR-negative cases cannot be stimulated by NEU3. Furthermore, NEU3‐mediated hyperactivation of EGFR is counterbalanced by the administration of cetuximab, hypothesizing that a combined treatment of NEU3‐ and EGFR‐targeted therapies may represent a valid option for CRC patients, which must be investigated in the future.

Bovio, F., Epistolio, S., Mozzi, A., Monti, E., Fusi, P., Forcella, M., et al. (2020). Role of NEU3 overexpression in the prediction of efficacy of EGFR‐targeted therapies in colon cancer cell lines. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 21(22), 1-18 [10.3390/ijms21228805].

Role of NEU3 overexpression in the prediction of efficacy of EGFR‐targeted therapies in colon cancer cell lines

Bovio F.;Mozzi A.;Fusi P.;Forcella M.;
2020

Abstract

The epidermal growth factor receptor (EGFR), through the MAP kinase and PI3K‐Akt-mTOR axis, plays a pivotal role in colorectal cancer (CRC) pathogenesis. The membrane‐associated NEU3 sialidase interacts with and desialylates EGFR by promoting its dimerization and downstream effectors’ activation. Among the targeted therapies against EGFR, the monoclonal antibody cetuximab is active only in a subgroup of patients not carrying mutations in the MAP kinase pathway. In order to better understand the EGFR‐NEU3 interplay and the mechanisms of pharmacological resistance, we investigated the role of NEU3 deregulation in cetuximab‐treated CRC cell lines transiently transfected with NEU3 using Western blot analysis. Our results indicate that NEU3 overexpression can enhance EGFR activation only if EGFR is overexpressed, indicating the existence of a threshold for NEU3‐mediated EGFR activation. This enhancement mainly leads to the constitutive activation of the MAP kinase pathway. Consequently, we suggest that the evaluation of NEU3 expression cannot entirely substitute the evaluation of EGFR because EGFR-negative cases cannot be stimulated by NEU3. Furthermore, NEU3‐mediated hyperactivation of EGFR is counterbalanced by the administration of cetuximab, hypothesizing that a combined treatment of NEU3‐ and EGFR‐targeted therapies may represent a valid option for CRC patients, which must be investigated in the future.
Articolo in rivista - Articolo scientifico
Scientifica
Cell lines; Cetuximab; Colorectal cancer; EGFR pathway; Sialidase NEU3;
English
Bovio, F., Epistolio, S., Mozzi, A., Monti, E., Fusi, P., Forcella, M., et al. (2020). Role of NEU3 overexpression in the prediction of efficacy of EGFR‐targeted therapies in colon cancer cell lines. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 21(22), 1-18 [10.3390/ijms21228805].
Bovio, F; Epistolio, S; Mozzi, A; Monti, E; Fusi, P; Forcella, M; Frattini, M
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/298682
Citazioni
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
Social impact